PDCD1 and melanoma: PPAR agonist is observed to induce FAO in T cells and enhance PD-1 blockade therapy in melanoma (36), which suggest that increasing catabolism of fatty acids in CD8+ T cells may enhance antitumor ability in the glucose deprivation and hypoxia TME.